Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PPP1R9A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PPP1R9A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PPP1R9A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PPP1R9A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PPP1R9A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PPP1R9A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0050807 | Colorectum | AD | regulation of synapse organization | 60/3918 | 211/18723 | 5.67e-03 | 3.64e-02 | 60 |
GO:0120032 | Colorectum | AD | regulation of plasma membrane bounded cell projection assembly | 53/3918 | 186/18723 | 8.51e-03 | 4.97e-02 | 53 |
GO:00070151 | Colorectum | SER | actin filament organization | 134/2897 | 442/18723 | 1.39e-15 | 5.70e-13 | 134 |
GO:00325351 | Colorectum | SER | regulation of cellular component size | 115/2897 | 383/18723 | 3.04e-13 | 1.10e-10 | 115 |
GO:00081541 | Colorectum | SER | actin polymerization or depolymerization | 77/2897 | 218/18723 | 3.50e-13 | 1.19e-10 | 77 |
GO:01100531 | Colorectum | SER | regulation of actin filament organization | 91/2897 | 278/18723 | 4.33e-13 | 1.40e-10 | 91 |
GO:00300411 | Colorectum | SER | actin filament polymerization | 70/2897 | 191/18723 | 5.39e-13 | 1.65e-10 | 70 |
GO:00080641 | Colorectum | SER | regulation of actin polymerization or depolymerization | 69/2897 | 188/18723 | 7.29e-13 | 1.95e-10 | 69 |
GO:19029031 | Colorectum | SER | regulation of supramolecular fiber organization | 114/2897 | 383/18723 | 7.32e-13 | 1.95e-10 | 114 |
GO:00308321 | Colorectum | SER | regulation of actin filament length | 69/2897 | 189/18723 | 9.76e-13 | 2.39e-10 | 69 |
GO:00308331 | Colorectum | SER | regulation of actin filament polymerization | 64/2897 | 172/18723 | 2.42e-12 | 5.70e-10 | 64 |
GO:00329701 | Colorectum | SER | regulation of actin filament-based process | 115/2897 | 397/18723 | 4.16e-12 | 8.80e-10 | 115 |
GO:00322711 | Colorectum | SER | regulation of protein polymerization | 78/2897 | 233/18723 | 5.71e-12 | 1.17e-09 | 78 |
GO:00512581 | Colorectum | SER | protein polymerization | 91/2897 | 297/18723 | 2.72e-11 | 5.06e-09 | 91 |
GO:00432541 | Colorectum | SER | regulation of protein-containing complex assembly | 119/2897 | 428/18723 | 3.34e-11 | 5.86e-09 | 119 |
GO:00329561 | Colorectum | SER | regulation of actin cytoskeleton organization | 104/2897 | 358/18723 | 3.68e-11 | 6.11e-09 | 104 |
GO:00106391 | Colorectum | SER | negative regulation of organelle organization | 90/2897 | 348/18723 | 3.14e-07 | 1.69e-05 | 90 |
GO:00096361 | Colorectum | SER | response to toxic substance | 71/2897 | 262/18723 | 8.63e-07 | 4.07e-05 | 71 |
GO:19029041 | Colorectum | SER | negative regulation of supramolecular fiber organization | 50/2897 | 167/18723 | 1.63e-06 | 7.23e-05 | 50 |
GO:01060271 | Colorectum | SER | neuron projection organization | 33/2897 | 93/18723 | 1.64e-06 | 7.23e-05 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP1R9A | SNV | Missense_Mutation | | c.1574N>T | p.Ala525Val | p.A525V | Q9ULJ8 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
PPP1R9A | SNV | Missense_Mutation | novel | c.4086G>T | p.Lys1362Asn | p.K1362N | Q9ULJ8 | protein_coding | deleterious_low_confidence(0) | benign(0.031) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PPP1R9A | SNV | Missense_Mutation | novel | c.1435N>G | p.Asn479Asp | p.N479D | Q9ULJ8 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A7-A13H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | PD |
PPP1R9A | SNV | Missense_Mutation | | c.3736N>A | p.Asp1246Asn | p.D1246N | Q9ULJ8 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP1R9A | SNV | Missense_Mutation | | c.3711N>C | p.Leu1237Phe | p.L1237F | Q9ULJ8 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PPP1R9A | SNV | Missense_Mutation | novel | c.916N>C | p.Ser306Pro | p.S306P | Q9ULJ8 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PPP1R9A | SNV | Missense_Mutation | novel | c.1534N>T | p.Asp512Tyr | p.D512Y | Q9ULJ8 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPP1R9A | SNV | Missense_Mutation | | c.3338N>A | p.Cys1113Tyr | p.C1113Y | Q9ULJ8 | protein_coding | tolerated(0.16) | benign(0) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PPP1R9A | SNV | Missense_Mutation | novel | c.844G>C | p.Val282Leu | p.V282L | Q9ULJ8 | protein_coding | tolerated(0.25) | benign(0.03) | TCGA-E9-A1RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
PPP1R9A | SNV | Missense_Mutation | | c.643N>A | p.Pro215Thr | p.P215T | Q9ULJ8 | protein_coding | tolerated(0.43) | benign(0.049) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |